Beneficial effects of rituximab therapy for systemic lupus erythematosus

Indian Journal of Pediatrics

Volumn 74, Issue 1, 2007, Pages 79-82

  Menon, Shina ^a   Hari, Pankaj ^a   Bagga, Arvind ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

B lymphocytes; Lupus nephritis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; ENALAPRIL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISOLONE; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ARTHRITIS; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; FEMALE; FEVER; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; MICROSCOPY; RASH; RECURRENT DISEASE; REMISSION; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; CHILD; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; RISK FACTOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33847117362     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12098-007-0033-y     Document Type: Article

References (15)

1. Ardoin SP, Schanberg LE. The management of pediatric systemic lupus erythematosus. Nature Clin Prac Rheum 2005; 1: 82-92.
2. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
3. Salama AD, Pusey CD. Drug insight: rituxumab in renal disease and transplantation. Nature Clin Prac Nephrol 2006; 2: 221-230.
4. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-620.
5. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nature Immunol 2001; 2: 764-766.
6. Gottenberg J-E, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-920.
7. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 1542-1545
8. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
9. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune hemolytic anemia in a patient with systemic lupus erythematosus. Br J Hematol 2002; 116: 465-467.
10. ten Cate R, Smiers FJ, Bredius RG, Lankester AC, van Suijlekom-Smit LW, Huizinga TW, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 244.
11. Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol 2005; 20: 811-813.
12. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3168-3174.
13. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P et al. French Pediatric-Onset SLE Study Group. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006; 148: 623-627.
14. Kunzmann V, Ruediger T, Hallek M, Mueller-Hermelink HK, Wilhelm M. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood 2001; 98: 1991-1992.
15. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transpl 2006; 6: 859-866.